Advertisement

Journal of Neurology

, Volume 264, Issue 12, pp 2481–2486 | Cite as

Quality of life predictors in patients with chronic inflammatory demyelinating polyradiculoneuropathy

  • Ivo Bozovic
  • Aleksandra Kacar
  • Stojan Peric
  • Ana Nikolic
  • Bogdan Bjelica
  • Mina Cobeljic
  • Milutin Petrovic
  • Aleksandar Stojanov
  • Vanja Djuric
  • Miroslav Stojanovic
  • Gordana Djordjevic
  • Vesna Martic
  • Aleksandra Dominovic
  • Zoran Vukojevic
  • Ivana Basta
Original Communication

Abstract

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a chronic disease which can lead to many functional impairments, and like most other chronic disorders it might significantly affect quality of life (QoL). Information about QoL in patients with CIDP from developing countries is still lacking. We, therefore, sought to complete these data mosaic by investigating QoL in patients with CIDP from Serbia and surrounding countries. Our study comprised 106 patients diagnosed with CIDP. QoL was investigated using the Serbian version of the SF-36 questionnaire. The Medical Research Council 0–5 point scale, INCAT motor and sensory scores, Krupp’s Fatigue Severity Scale, and Beck Depression Inventory were also used. Factors that significantly correlated with SF-36 total score in univariate analysis were included in the multiple linear regression analysis. Physical domains of the SF-36 were more affected than mental, and the overall score was 56.6 ± 25.4. Significant predictors of worse SF-36 score in our patients with CIDP were severe fatigue (β = − 0.331, p < 0.01), higher INCAT motor score (β = − 0.301, p < 0.01), depression (β = − 0.281, p < 0.01), being unemployed/retired (β = − 0.188, p < 0.05), and shorter duration of CIDP (β = + 0.133, p < 0.01). QoL was reduced in CIDP patients, especially in physical domains. Patients with presence of fatigue and depression, with more severe motor disability, unemployed/retired ones, and those with shorter duration of the disease need special attention of clinicians since they could be at higher risk to have worse QoL.

Keywords

Chronic inflammatory demyelinating polyradiculoneuropathy Quality of life SF-36 Predictors Fatigue Depression 

Notes

Compliance with ethical standards

Conflicts of interest

None of the authors has any conflict of interest to disclose.

Ethical standards

All authors comply with Springer’s ethical policies.

References

  1. 1.
    Van den Bergh PYK, Hadden RDM, Bouche P, Cornblath DR, Hahn A, Illa I et al (2010) European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripher. Eur J Neurol 17(3):356–363CrossRefPubMedGoogle Scholar
  2. 2.
    Harbo T, Andersen H, Overgaard K, Jakobsen J (2008) Muscle performance relates to physical function and quality of life in long-term chronic inflammatory demyelinating polyradiculoneuropathy. J Peripher Nerv Syst 13(3):208–217CrossRefPubMedGoogle Scholar
  3. 3.
    Rajabally YA, Seri S, Cavanna AE (2016) Neuropsychiatric manifestations in inflammatory neuropathies: a systematic review. Muscle Nerve 54(1):1–8CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Merkies ISJ, Kieseier BC (2016) Fatigue, pain, anxiety and depression in Guillain–Barré syndrome and chronic inflammatory demyelinating polyradiculoneuropathy. Eur Neurol 75(3–4):199–206CrossRefPubMedGoogle Scholar
  5. 5.
    Goebel A, Lecky B, Smith L-J, Lunn MP (2012) Pain intensity and distribution in chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 46(2):294–295CrossRefPubMedGoogle Scholar
  6. 6.
    Rajabally YA, Cavanna AE (2015) Health-related quality of life in chronic inflammatory neuropathies: a systematic review. J Neurol Sci 348(1–2):18–23CrossRefPubMedGoogle Scholar
  7. 7.
    Westblad ME, Forsberg A, Press R (2009) Disability and health status in patients with chronic inflammatory demyelinating polyneuropathy. Disabil Rehabil 31(9):720–725CrossRefPubMedGoogle Scholar
  8. 8.
    Draak THP, Vanhoutte EK, van Nes SI, Gorson KC, Van der Pol WL, Notermans NC et al (2014) Changing outcome in inflammatory neuropathies: Rasch-comparative responsiveness. Neurology 83(23):2124–2132CrossRefPubMedGoogle Scholar
  9. 9.
    Merkies ISJ, Hughes RAC, Donofrio P, Bril V, Dalakas MC, Hanna K et al (2010) Understanding the consequences of chronic inflammatory demyelinating polyradiculoneuropathy from impairments to activity and participation restrictions and reduced quality of life: the ICE study. J Peripher Nerv Syst 15(3):208–215CrossRefPubMedGoogle Scholar
  10. 10.
    Kleyweg RP, van der Meché FG, Schmitz PI (1991) Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain–Barré syndrome. Muscle Nerve 14(11):1103–1109CrossRefPubMedGoogle Scholar
  11. 11.
    Breiner A, Barnett C, Bril V (2014) INCAT disability score: a critical analysis of its measurement properties. Muscle Nerve 50(2):164–169CrossRefPubMedGoogle Scholar
  12. 12.
    Draak THP, Vanhoutte EK, van Nes SI, Gorson KC, Van der Pol W-L, Notermans NC et al (2015) Comparing the NIS vs. MRC and INCAT sensory scale through Rasch analyses. J Peripher Nerv Syst 20(3):277–288CrossRefPubMedGoogle Scholar
  13. 13.
    Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD (1989) The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 46(10):1121–1123CrossRefPubMedGoogle Scholar
  14. 14.
    Beck AT, Steer RA, Carbin MG (1988) Psychometric properties of the Beck Depression Inventory: twenty-five years of evaluation. Clin Psychol Rev 8(1):77–100CrossRefGoogle Scholar
  15. 15.
    SF-36 Health Survey (original version) language recalls. http://www.qualitymetric.com. Accessed Jan 2017
  16. 16.
    Erdmann PG, van Meeteren NLU, Kalmijn S, Wokke JHJ, Helders PJM, van den Berg LH (2005) Functional health status of patients with chronic inflammatory neuropathies. J Peripher Nerv Syst 10(2):181–189CrossRefPubMedGoogle Scholar
  17. 17.
    dos Santos PL, de Almeida-Ribeiro GAN, Silva DMD, Marques Junior W, Barreira AA (2014) Chronic inflammatory demyelinating polyneuropathy: quality of life, sociodemographic profile and physical complaints. Arq Neuropsiquiatr 72(3):179–183CrossRefPubMedGoogle Scholar
  18. 18.
    Harbo T, Andersen H, Hess A, Hansen K, Sindrup SH, Jakobsen J (2009) Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: a randomized, single-blinded cross-over trial. Eur J Neurol 16(5):631–638CrossRefPubMedGoogle Scholar
  19. 19.
    Stangel M, Gold R, Pittrow D, Baumann U, Borte M, Fasshauer M et al (2016) Treatment of patients with multifocal motor neuropathy with immunoglobulins in clinical practice: the SIGNS registry. Ther Adv Neurol Disord 9(3):165–179CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Braine ME, Woodall A (2012) A comparison between intravenous and subcutaneous immunoglobulin. Br J Nurs 21(8):21–27CrossRefGoogle Scholar
  21. 21.
    Merkies IS, Schmitz PI, Samijn JP, van der Meché FG, van Doorn PA (1999) Fatigue in immune-mediated polyneuropathies. European Inflammatory Neuropathy Cause and Treatment (INCAT) Group. Neurology 53(8):1648–1654CrossRefPubMedGoogle Scholar
  22. 22.
    Boldingh MI, Dekker L, Maniaol AH, Brunborg C, Lipka AF, Niks EH et al (2015) An up-date on health-related quality of life in myasthenia gravis—results from population based cohorts. Health Qual Life Outcomes 13(1):115CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Winter Y, Schepelmann K, Spottke AE, Claus D, Grothe C, Schröder R et al (2010) Health-related quality of life in ALS, myasthenia gravis and facioscapulohumeral muscular dystrophy. J Neurol 257(9):1473–1481CrossRefPubMedGoogle Scholar
  24. 24.
    Redmond AC, Burns J, Ouvrier RA (2008) Factors that influence health-related quality of life in Australian adults with Charcot–Marie–Tooth disease. Neuromuscul Disord 18(8):619–625CrossRefPubMedGoogle Scholar
  25. 25.
    Peric S, Stojanovic VR, Basta I, Peric M, Milicev M, Pavlovic S et al (2013) Influence of multisystemic affection on health-related quality of life in patients with myotonic dystrophy type 1. Clin Neurol Neurosurg 115(3):270–275CrossRefPubMedGoogle Scholar
  26. 26.
    Rakocevic Stojanovic V, Peric S, Paunic T, Pesovic J, Vujnic M, Peric M et al (2016) Quality of life in patients with myotonic dystrophy type 2. J Neurol Sci 365:158–161CrossRefPubMedGoogle Scholar
  27. 27.
    Merkies ISJ, van Nes SI, Hanna K, Hughes RAC, Deng C (2010) Confirming the efficacy of intravenous immunoglobulin in CIDP through minimum clinically important differences: shifting from statistical significance to clinical relevance. J Neurol Neurosurg Psychiatry 81(11):1194–1199CrossRefPubMedGoogle Scholar
  28. 28.
    Renoir T, Hasebe K, Gray L (2013) Mind and body: how the health of the body impacts on neuropsychiatry. Front Pharmacol 4:158PubMedPubMedCentralGoogle Scholar
  29. 29.
    Mahdi-Rogers M, McCrone P, Hughes RAC (2014) Economic costs and quality of life in chronic inflammatory neuropathies in southeast England. Eur J Neurol 21(1):34–39CrossRefPubMedGoogle Scholar
  30. 30.
    Garssen MPJ, Bussmann JBJ, Schmitz PIM, Zandbergen A, Welter TG, Merkies ISJ et al (2004) Physical training and fatigue, fitness, and quality of life in Guillain–Barré syndrome and CIDP. Neurology 63(12):2393–2395CrossRefPubMedGoogle Scholar
  31. 31.
    Boukhris S, Magy L, Gallouedec G, Khalil M, Couratier P, Gil J et al (2005) Fatigue as the main presenting symptom of chronic inflammatory demyelinating polyradiculoneuropathy: a study of 11 cases. J Peripher Nerv Syst 10(3):329–337CrossRefPubMedGoogle Scholar
  32. 32.
    Merkies ISJ, Faber CG (2012) Fatigue in immune-mediated neuropathies. Neuromuscul Disord 22:S203–S207CrossRefPubMedGoogle Scholar
  33. 33.
    Nobile-Orazio E, Cocito D, Jann S, Uncini A, Messina P, Antonini G et al (2015) Frequency and time to relapse after discontinuing 6-month therapy with IVIg or pulsed methylprednisolone in CIDP. J Neurol Neurosurg Psychiatry 86(7):729–734CrossRefPubMedGoogle Scholar
  34. 34.
    Eftimov F, Vermeulen M, van Doorn PA, Brusse E, van Schaik IN (2012) PREDICT. Long-term remission of CIDP after pulsed dexamethasone or short-term prednisolone treatment. Neurology 78(14):1079–1084CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany 2017

Authors and Affiliations

  • Ivo Bozovic
    • 1
  • Aleksandra Kacar
    • 1
  • Stojan Peric
    • 1
  • Ana Nikolic
    • 1
  • Bogdan Bjelica
    • 1
  • Mina Cobeljic
    • 1
  • Milutin Petrovic
    • 2
  • Aleksandar Stojanov
    • 3
  • Vanja Djuric
    • 4
  • Miroslav Stojanovic
    • 2
  • Gordana Djordjevic
    • 3
  • Vesna Martic
    • 5
  • Aleksandra Dominovic
    • 6
  • Zoran Vukojevic
    • 6
  • Ivana Basta
    • 1
  1. 1.Neurology Clinic, Clinical Center of Serbia, School of MedicineUniversity of BelgradeBelgradeSerbia
  2. 2.Neurology ClinicClinical Center KragujevacKragujevacSerbia
  3. 3.Neurology ClinicClinical Center NisNisSerbia
  4. 4.Outpatient Neurology Clinic “Neuromedic”NisSerbia
  5. 5.Neurology ClinicMilitary Medical AcademyBelgradeSerbia
  6. 6.Neurology ClinicClinical Center Banja LukaBanja LukaBosnia and Herzegovina

Personalised recommendations